effect of lactobacillus plantarum is-10506 on blood lipopolysaccharide level and immune response in hiv-infected children

Background and objectives: hiv enteropathy may cause disruption of the intestinal barrier, leading to a loss of cd4+ t cells, increased intestinal permeability, and microbial translocation. lactobacillus plantarum is-10506 has the ability to improve gut barrier function. this study investigated the effect of l. plantarum is-10506 on a number of biomarkers of enteropathy-related damage in hiv-infected paediatric patients undergoing antiretroviral therapy (arv). materials and methods: a randomized, double-blind, placebo-controlled study was conducted on 2-18 year-old children, diagnosed as hiv infected according to the who 2007 criteria who had received arv for ≥ 6 months. subjects were exclud- ed if arv therapy was discontinued or the patients took probiotics ≥ 2 weeks prior to the study or during the study period. subjects were randomized into a probiotic group and placebo group. the probiotic group received l. plantarum is-10506 2.86 × 10^10 cfu/day for 6 days. blood lipopolysaccharide (lps) level, serum cd4+ t cell count, serum cd8+ t cell count, cd4+/cd8+ t cell ratio, and faecal siga level were assessed as biomarkers. results: twenty-one subjects completed this study. the blood lps level decreased significantly in the probiotic group (p = 0.001). there was no significant difference in absolute cd4+ t cell count, percent cd4+ cells, absolute cd8+ t cell count, cd4+/cd8+ t cell ratio, or faecal siga. no serious adverse events were reported. conclusion: the probiotic l. plantarum is-10506 reduced the blood lps level but showed no effect on the humoral mucosa and systemic immune response in hiv-infected children undergoing arv therapy.